Table 3.

Multivariate Cox regression analyses of factors affecting the transplant-free survival in patients with PSC

Oslo cohorta	sCD163, ELF, and AOM			sMR, ELF, and AOM
	HR	95% CI	P Value	HR	95% CI	P Value
AOM, per point increase	1.77	1.21–2.58	0.003	1.77	1.21–2.59	0.003
ELF test, per point increase	1.51	1.17–1.96	0.002	1.56	1.24–1.95	<0.001
LnsCD163	1.03	0.54–1.97	0.92	—	—	—
LnsMR	—	—	—	0.91	0.48–1.73	0.78

Helsinki cohortb	sCD163, ELF, and AOM			sMR, ELF, and AOM
	HR	95% CI	P Value	HR	95% CI	P Value
AOM, per point increase	0.84	0.30–2.32	0.74	0.72	0.25–2.06	0.54
ELF test, per point increase	2.91	1.42–5.94	0.003	2.62	1.47–4.69	0.001
LnsCD163	0.70	0.17–2.92	0.63	—	—	—
LnsMR	—	—	—	1.64	0.27–10.13	0.59

Combined cohortc	sCD163, ELF, and AOM			sMR, ELF, and AOM
	HR	95% CI	P Value	HR	95% CI	P Value
AOM, per point increase	1.65	1.15–2.38	0.007	1.65	1.15–2.37	0.007
ELF test, per point increase	1.66	1.31–2.10	<0.001	1.66	1.35–2.04	<0.001
LnsCD163	0.92	0.52–1.63	0.78	—	—	—
LnsMR	—	—	—	0.89	0.50–1.60	0.70
Center (Oslo = reference)	0.64	0.33–1.25	0.19	0.66	0.34–1.27	0.21

^aCalculated in a subset of 128 patients with available AOM, events n = 60.

^bCalculated in a subset of 64 patients with available AOM, events n = 12.

^cCalculated in a subset of 192 patients with available AOM, events n = 72.

AOM, Amsterdam-Oxford Model for primary sclerosing cholangitis; CI, confidence interval; HR, hazard ratio; LnsCD163, logarithmic transformed soluble CD163; LnsMR, logarithmic transformed soluble mannose receptor; PSC, primary sclerosing cholangitis; sCD163, soluble CD163; sMR, soluble mannose receptor.